SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fredun Pharmaceuticals moves up on acquiring Wagr

10 Oct 2025 Evaluate

Fredun Pharmaceuticals is currently trading at Rs. 1430.00, up by 11.30 points or 0.80% from its previous closing of Rs. 1418.70 on the BSE.

The scrip opened at Rs. 1421.00 and has touched a high and low of Rs. 1450.85 and Rs. 1411.00 respectively. So far 1747 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 1455.00 on 06-Oct-2025 and a 52 week low of Rs. 635.00 on 16-Jan-2025.

Last one week high and low of the scrip stood at Rs. 1455.00 and Rs. 1390.00 respectively. The current market cap of the company is Rs. 684.64 crore.

The promoters holding in the company stood at 48.93%, while Institutions and Non-Institutions held 1.59% and 49.48% respectively.

Fredun Pharmaceuticals (FPL) has acquired all assets of Wagr, a leading pet tech platform, marking the launch of India's first truly neutral online marketplace for pet products and services. This strategic move positions FPL at the forefront of India's rapidly growing pet care industry, projected to reach $6 billion by 2030.

The acquisition includes Wagr's comprehensive technology platform, user base of 140,000+ pet parents, patented pet fitness tracking technology, and established veterinary network-creating an unprecedented ecosystem that addresses critical gaps in the Indian pet care market. FPL will relaunch the Wagr marketplace and services in Q4 FY 2025-26. 

Fredun Pharmaceuticals is engaged in manufacturing of pharmaceutical products.


Fredun Pharma Share Price

2122.40 54.70 (2.65%)
21-Apr-2026 09:39 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.00
Dr. Reddys Lab 1224.90
Cipla 1230.50
Zydus Lifesciences 931.00
Lupin 2335.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×